Why the study?
Do plasma levels of fibrinopeptide A and beta-thromboglobulin differentiate between myocardial infarction, unstable angina, and noncardiac causes in patients with acute chest pain?
Do plasma levels of fibrinopeptide A and beta-thromboglobulin differentiate between myocardial infarction, unstable angina, and noncardiac causes in patients with acute chest pain?
Plasma fibrinopeptide A levels are elevated in patients with acute chest pain but do not specifically distinguish myocardial infarction or ischemic chest pain from noncardiac causes.
Fibrinopeptide A elevation does not distinguish ischemic from noncardiac chest pain; leaves open diagnostic utility pending prospective studies.
Plasma levels of beta-thromboglobulin (BTG) and fibrinopeptide A (FPA), markers of platelet release and thrombin generation respectively, were measured in 48 patients within 3 days of admission to hospital for acute chest pain. Twenty-one patients had a confirmed myocardial infarction (MI); 15 had unstable angina without infarction; and 12 had chest pain due to noncardiac causes. FPA and BTG were also measured in 23 control hospital patients of similar age. Mean plasma BTG levels were not significantly different in the 4 groups. Mean plasma FPA levels were significantly higher in all 3 groups with acute chest pain when compared to the control subjects (p less than 0.01), but there were no significant differences between the 3 groups. Increased FPA levels in patients with acute chest pain are not specific for myocardial infarction, nor for ischaemic chest pain.
No takes yet. Share an insight, caveat, or question.
Douglas et al. (1983) studied Chest Pain. Plasma Fibrinopeptide A and Beta-Thromboglobulin was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: